TRV GP VI’s Rapport Therapeutics RAPP Stock Holding History

TRV GP VI’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.4M	Hold	969,218	–	–	17.39%	3
2026 Q1	$30.3M	Hold	969,218	–	–	22.37%	2
2025 Q4	$29.4M	Hold	969,218	–	–	19.8%	2
2025 Q3	$28.8M	Hold	969,218	–	–	26.26%	2
2025 Q2	$11M	Hold	969,218	–	–	17.16%	2
2025 Q1	$9.72M	Hold	969,218	–	–	23.16%	2
2024 Q4	$17.2M	Buy	+969,218	New	+$21.5M	14.71%	3

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

TRV GP VI's RAPP Position: Q2 2026 in Review

TRV GP VI held its Rapport Therapeutics (RAPP) position steady in Q2 2026 at 969,218 shares worth $40.4M. The position accounts for 17.39% of the portfolio, ranked #3.

TRV GP VI first reported a position in RAPP in Q4 2024 and has held it in 7 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

TRV GP VI held 969,218 shares of Rapport Therapeutics worth $40.4M as of Q2 2026.
TRV GP VI left its Rapport Therapeutics share count unchanged in Q2 2026.
Rapport Therapeutics made up 17.39% of TRV GP VI's portfolio in Q2 2026, its #3 holding.
TRV GP VI first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 7 quarters since.
160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on TRV GP VI's 13F filing for Q2 2026, filed 10 Aug 2026.